Zembrace Symtouch (autoinjector) is a drug owned by Tonix Medicines Inc. It is protected by 3 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 29, 2036. Details of Zembrace Symtouch (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10537554 | Pharmaceutical composition for treating migraine |
Jan, 2036
(9 years from now) | Active |
| US11364224 | Pharmaceutical composition for treating migraine |
Jan, 2036
(9 years from now) | Active |
| US12097183 | Pharmaceutical composition for treating migraine |
Jan, 2036
(9 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Zembrace Symtouch (autoinjector) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zembrace Symtouch (autoinjector)'s family patents as well as insights into
ongoing legal events
on those patents.
Zembrace Symtouch (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zembrace Symtouch (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 29, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zembrace Symtouch (autoinjector) Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Zembrace Symtouch (autoinjector). 31 different companies have already filed for the generic of Zembrace Symtouch (autoinjector), with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zembrace Symtouch (autoinjector)'s generic
Alternative Brands for Zembrace Symtouch (autoinjector)
There are several other brand drugs using the same active ingredient (Sumatriptan Succinate) as Zembrace Symtouch (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Endo Operations |
| ||
| Meridian Medcl |
| ||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Zembrace Symtouch (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Zembrace Symtouch (autoinjector)
About Zembrace Symtouch (autoinjector)
Zembrace Symtouch (Autoinjector) is a drug owned by Tonix Medicines Inc. Zembrace Symtouch (Autoinjector) uses Sumatriptan Succinate as an active ingredient. Zembrace Symtouch (Autoinjector) was launched by Tonix Meds in 2016.
Approval Date:
Zembrace Symtouch (autoinjector) was approved by FDA for market use on 28 January, 2016.
Active Ingredient:
Zembrace Symtouch (autoinjector) uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Dosage:
Zembrace Symtouch (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | SOLUTION | Prescription | SUBCUTANEOUS |